NCT03548155 is a NA clinical trial of Berberine in Schizophrenia, sponsored by Tianjin Anding Hospital.

Who is sponsoring NCT03548155?

NCT03548155 is sponsored by Tianjin Anding Hospital.

What drugs are being tested in NCT03548155?

Interventions in NCT03548155: Berberine, atypical antipsychotic, placebo.

What condition does NCT03548155 study?

NCT03548155 studies Schizophrenia, Therapeutics.

Is NCT03548155 still recruiting?

NCT03548155 is currently completed. Last updated 25 July 2023.

Last reviewed 2023-07-25 · How we verify

NCT03548155

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Berberine Effects on Clinical Symptoms and Metabolic Disturbance in Patients With Schizophrenia

Completed NA Last updated 25 July 2023

What this trial tests

NA trial testing Berberine in Schizophrenia in 65 participants. Completed in 8 May 2017.

Timeline

24 July 2014

Primary endpoint
14 December 2015

8 May 2017

Quick facts

Lead sponsor	Tianjin Anding Hospital
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	65
Start date	24 July 2014
Primary completion	14 December 2015
Estimated completion	8 May 2017

Drugs / interventions tested

Berberine — full drug profile →
atypical antipsychotic — full drug profile →
placebo

Conditions studied

Schizophrenia — all drugs for Schizophrenia →
Therapeutics — all drugs for Therapeutics →

Sponsor

Tianjin Anding Hospital

Who can join

Adults 18 to 62, any sex, with Schizophrenia or Therapeutics. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The study was a 8-week, randomized, double-blind, placebo-controlled trial. Berberine (300 mg，three times a day), as an adjuvant therapy has been used on the basis of the Second-generation antipsychotics（SGAs） monotherapy. All participants were randomly divided into two groups.Any SGA + berberine (BBR) or any SGA +placebo.Positive and Negative Syndrome Scale (PANSS) has been used for psychiatric symptoms.The treatment Emergent Symptom Scale(TESS) has been used for evaluate adverse effects.Glucose and lipid profile, inflammatory factors，adiponectin，leptin were obtained at 0, 4,8 weeks.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Revolutionizing Ischemic Stroke Diagnosis and Treatment: The Promising Role of Neurovascular Unit-Derived Extracellular Vesicles.
Gao X, Liu D, Yue K, Zhang Z, et al · · 2024 · cited 12× · PMID 38540796 · DOI 10.3390/biom14030378
Improvement of adjunctive berberine treatment on negative symptoms in patients with schizophrenia.
Li M, Qiu Y, Zhang J, Zhang Y, et al · · 2022 · cited 12× · PMID 35037116 · DOI 10.1007/s00406-021-01359-4

Verify or expand the search:

Other trials of Berberine

Trials testing the same drug.

NCT07420231 — Evaluation of the Synergistic Effect of Combining a Prebiotic and a Postbiotic on Intestinal Discomfort · NA · not yet recruiting
NCT07480018 — Berberine Supplementation, Sprint Interval Training, and Immune Function Study · NA · recruiting
NCT06911983 — Comparative Efficacy of Metformin and Berberine Among TCF7L2 (rs7903146) TT vs. CC Genotype Carriers With Type 2 Diabete · NA · not yet recruiting
NCT05720299 — A Clinical Study to Evaluate the Effects of Akkermansia Muciniphila and Berberine on Prediabetes Among Obese Subjects. · NA · completed
NCT06514274 — Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Era · Phase 4 · completed

Other recruiting trials for Schizophrenia

Currently open trials in the same condition.

NCT07424404 — A Study to Evaluate the Long-term Safety and Tolerability of KarXT and KarX-EC for the Treatment of Schizophrenia and Au · Phase 3 · recruiting
NCT07467993 — Study to Assess the Safety, Tolerability, and Treatment Response of GXV813 in Hospitalized Adults With Schizophrenia · Phase 2 · recruiting
NCT07379827 — Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) · recruiting
NCT06758414 — CBT-CP for Veterans With SMI · NA · recruiting
NCT07395206 — Acceptability, Feasibility and Preliminary Outcomes of the Kiso Mind App for Outpatients With Schizophrenia Spectrum Dis · NA · recruiting

Other Tianjin Anding Hospital trials

Trials by the same sponsor.

NCT07393464 — PQQ for Cognitive and Negative Symptoms · NA · not yet recruiting
NCT07523490 — Investigation on Suicide Risk Factors of Patients With Mood Disorders · recruiting
NCT06812923 — TACS on High-inflammatory and Refractory Depression · NA · recruiting
NCT07162467 — Tryptophan-Kynurenine Pathway Metabolism in the Pathophysiology of Cognitive Impairment in Schizophrenia. · enrolling by invitation
NCT07359209 — Berberine Improving Cognitive Impairments in Schizophrenia · NA · enrolling by invitation

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03548155 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Tianjin Anding Hospital
Last refreshed: 25 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03548155.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing